Lumos Drugs & Surgical Private Limited
Pharmaceutical and surgical product distribution and sales since 2018.
2018 | Kamrup, Assam (India) | Active
Lumos Drugs & Surgical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.70 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -38.94%
- Profit Growth 247.92%
- Ebitda 283.13%
- Net Worth 45.99%
- Total Assets -29.14%
About Lumos Drugs & Surgical
Lumos Drugs & Surgical Private Limited (LDSPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 November 2018 (Six years and two months 29 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M, as per Ministry of Corporate Affairs (MCA) records.
Tejash Phukan and Dhanjit Deka serve as directors at the Company.
Company Details
- Location
Kamrup, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909AS2018PTC018898
- Company No.
018898
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Healthcare
Pharma
Who are the key members and board of directors at Lumos Drugs & Surgical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tejash Phukan  | Director | 30-Nov-2018 | Current |
| Dhanjit Deka | Director | 30-Nov-2018 | Current |
Financial Performance of Lumos Drugs & Surgical.
Lumos Drugs & Surgical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 38.94% decrease. The company also saw a substantial improvement in profitability, with a 247.92% increase in profit. The company's net worth Soared by an impressive increase of 45.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lumos Drugs & Surgical?
In 2022, Lumos Drugs & Surgical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lumos Drugs & Surgical?
Unlock and access historical data on people associated with Lumos Drugs & Surgical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lumos Drugs & Surgical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lumos Drugs & Surgical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
